Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival

Journal of Gastrointestinal Surgery

Volumn 12, Issue 1, 2008, Pages 91-100

  Allendorf, John D ^a,b   Lauerman, Margaret ^a   Bill, Aliye ^a   Digiorgi, Mary ^a   Goetz, Nicole ^a   Vakiani, Efsevia ^a   Remotti, Helen ^a   Schrope, Beth ^a   Sherman, William ^a   Hall, Michael ^a   Fine, Robert L ^a   Chabot, John A ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b NONE   (United States)

Author keywords

Cancer; Gemcitabine; Neoadjuvant; Pancreas; Vascular

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GEMCITABINE; PRODRUG; RADIOSENSITIZING AGENT; RIBONUCLEOTIDE REDUCTASE;

ADENOCARCINOMA; ADJUVANT THERAPY; AGED; ARTICLE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG CONTRAINDICATION; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PANCREAS RESECTION; PANCREAS TUMOR; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; PRODRUGS; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; RIBONUCLEOTIDE REDUCTASES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 38149044917     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-007-0296-7     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol/Hematol 2006;58:231-241.
3. Molinari M, Helton WS, Espat NJ. Palliative strategies for locally advanced unresectable and metastatic pancreatic cancer. Surg Clin North Am 2001;81:651-658.
4. Xiong HQ, Carr K, Abbruzzese JL. Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions. Drugs 2006;66(8):1059-1072.
5. Fine RL, Fogelman DR, Sherman W. The GTX regimen: A biochemically synergistic combination for advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 2003;Abst # 1129.
6. Fine RL, Fogelman DR, Schreibman S, Guba S, Sharma J, Shapiro G. GTX chemotherapy for metastatic pancreatic cancer: Response, survival, and toxicity data. J Clin Oncol 2004;22:381s.
7. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot JC. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: A retrospective analysis. Cancer Chemother Pharmacol 2007 (in press).
8. Fogelman DR, Chen J, Chabot JA, Allendorf JD, Schrope BA, Ennis RD, Schreibman SM, Fine RL. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: From 5-fluorouracil to GTX. Surg Oncol Clin N Am 2004;13:711-736.
9. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States). Cancer Causes Control 2006;17:403-409.
10. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA. Six hundred and fifty consecutive pancreaticoduodenectomies in the 1990's: Pathology, complications, and outcomes. Ann Surg 1997;226:248-260.
11. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, Coleman J. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120-124.
12. Tashiro S, Uchino R, Hiraoka T, Tsuji T, Kawamoto S, Saitoh N, Yamasaki K, Miyauchi Y. Surgical indication and significance of portal vein resection in biliary and pancreatic cancer. Surgery 1991;109:481-487.
13. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13(8):1035-1046.
14. Poon RT, Fan ST. Opinions and commentary on treating pancreatic cancer. Surg Clin North Am 2001;81:625-636.
15. Evans DB, Lee JE, Pisters PWT. Pancreaticoduodenectomy (Whipple operation) and total pancreatectomy for cancer. In Nyhus LM, Baker RJ, Fischer JF, eds. Mastery of Surgery, 3rd ed. Boston: Little Brown, 1997, pp 1233-1249.
16. Holzman MD, Reintgen KL, Tyler DS, Pappas TN. The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. J Gastrointest Surg 1997;1:236-243.
17. Rumstadt B, Schwab M, Schuster K, Hagmuller E, Trede M. The role of laparoscopy in the preoperative staging of pancreatic carcinoma. J Gastrointest Surg 1997;1:245-250.
18. Jessup JM, Steele G Jr, Mayer RJ, Posner M, Busse P, Cady B, Stone M, Jenkins R, Osteen R. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993;128:559-564.
19. Kamthan AG, Morris JC, Dalton J, Mandeli JP, Chesser MR, Leben D, Cooperman A, Bruckner HW. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 1997;15:2920-2927.
20. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-2212.
21. Epelbaum R, Rosenblatt E, Nasrallah S, Faraggi D, Gaitini D, Mizrahi S, Kuten A. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 2002;81:138-143.
22. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89:314-327.
23. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, Lawrence TS, McGinn CJ. Surgical resection following radiation therapy with concurrent ge mcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003;7:766-772.